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Drug similarity studies are driven by the hypothesis that similar drugs should display similar 
therapeutic actions and thus can potentially treat a similar constellation of diseases.  Drug-drug 
similarity has been derived by variety of direct and indirect sources of evidence and frequently 
shown high predictive power in discovering validated repositioning candidates as well as other 
in-silico drug development applications. Yet, existing resources either have limited coverage or 
rely on an individual source of evidence, overlooking the wealth and diversity of drug-related 
data sources. Hence, there has been an unmet need for a comprehensive resource integrating 
diverse drug-related information to derive multi-evidenced drug-drug similarities.  We 
addressed this resource gap by compiling heterogenous information for an exhaustive set of 
small-molecule drugs (total of 10,367 in the current version) and systematically integrated 
multiple sources of evidence to derive a multi-modal drug-drug similarity network. The 
resulting database, DrugSimDB currently includes 238,635 drug pairs with significant 
aggregated similarity, complemented with an interactive user-friendly web interface 
(http://vafaeelab.com/drugSimDB.html) which not only enables database ease of access, 
search, filtration and export, but also provides a variety of complementary information on 
queried drugs and interactions.  The integration approach can flexibly incorporate further drug 
information into the similarity network, providing an easily extendable platform. The database 
compilation and construction source-code has been well-documented and semi-automated for 
any-time upgrade to account for new drugs and up-to-date drug information.   
Introduction 
Drug similarity studies rely on the assumption that drugs with similar pharmacological 
properties are similar in their mechanism of action, share similar side-effects and are indicated 
for the treatment of similar diseases [1, 2].  In-silico drug-drug similarity has been derived for a 
variety of applications including drug target identification [3-7], side-effect prediction [8-10], 
drug-drug interaction prediction [11-15] and drug repositioning [1, 16-19].  The latter, i.e., 
repositioning existing drugs for new indications, has received an escalated interest in the 
research and pharmaceutical industries as an innovative drug development strategy offering the 
possibility of reductions in cost, time and risk as several phases of de-novo drug discovery can 
be bypassed for repositioning candidates [20].  Drug similarity estimation can be directly 
incorporated into the repositioning pipeline to prioritise repositioning candidates based on the 
extent of their similarity with the drug of interest.  
A variety of drug-related sources of evidence—e.g., chemical structure characteristics [7, 21], 
protein targets [22, 23], side-effect profiles [6, 24], gene expression profiles [17, 25], and 
clinical information [2]—have been previously applied in drug-drug similarity analytics.  
Heterogeneous data sources provide a multi-view perspective for predicting similar drugs and 
can compensate for missing data across individual data sources. Hence, incorporating diverse 
data sources, can boost the coverage and accuracy of the prediction and provide new insights 
into drug repositioning and other applications.  Despite the current availability of several drug-
related data sources, there is a need for a comprehensive, contemporary knowledgebase 
integrating diverse information from a wide array of evidence sources to derive multi-modal 
drug-drug similarities.  
We addressed this resource gap by developing DrugSimDB which incorporates into similarity 
measures, multiple sources of direct and indirect information compiled on a comprehensive list 
of drugs. DrugSimDB covers 10,317 small molecule drugs—including 2,466 approved and 
7,212 experimental, illicit or withdrawn—and provides 238,635 pairs of drugs with significant, 
multi-modal similarity. Chemical structure descriptors, drug-induced pathways, drug-protein 
and protein-protein relationships as well as protein sequences and their functional annotations 
were compiled from diverse public datasets and used to estimate structure-, pathway-, target-, 
and function-based similarity between each pair of drugs. Similarity measures across 
modalities were aggregated and assessed for statistical significance. Comparing against a drug 
repositioning gold standard of approved and failed drugs, we have shown that diversifying 
sources of similarity evidence improves the specificity and sensitivity of candidate 
prioritisation for repositioning, which corroborates the necessity of multi-modal approaches 
and the utility of DrugSimDB for drug development.    
We implemented an inclusive web-application (http://vafaeelab.com/drugSimDB.html) 
enabling users to browse DrugSimDB for a drug of interest or download the full database or 
any intermediately-processed important files, e.g., individual pairwise similarity matrices. For 
each queried drug, in addition to a prioritised list of similar drugs, the web application provides 
information on a drug’s physicochemical and pharmacological properties as well as an 
interactive view of the drug’s 3D structure. More importantly, the web application provides an 
interactive visualisation of an induced subnetwork of the drug-drug similarity network 
including the queried drug and its interacting partners. A batch query is also supported, where 
users can upload a list of drugs (names/IDs) to retrieve their similarity information. Users can 
select any node on the subnetwork to probe a drug’s side-effects or select any edge to explore 
PubMed articles with evidence of the association. For improved reusability and maintenance of 
data coverage, we implemented the whole framework as a well-documented and semi-
automated, parallelised pipeline. Users can follow simple instructions to retrieve up-to-date 
data sources and update the database accordingly.  
Overall, DrugSimDB and its web application provide an exhaustive and reusable resource for 
multi-modal drug similarity investigation enriched with drug side-effect, indications, and 
literature evidence, which together form a unique starting point for drug-repositioning and 
beyond. 
Materials and methods 
Data sources 
Drug names, identifiers, physicochemical and pharmacological properties and links to external 
databases were retrieved from DrugBank [26], a comprehensive, frequently updated drug 
encyclopaedia. Drug chemical structures in SDF format, protein targets and their primary 
structure in FASTA format were also retrieved from DrugBank. Drug-induced pathways and 
their constituent genes were obtained from Kyoto Encyclopedia of Genes and Genomes 
(KEGG) [27]. Protein-protein interactions (PPIs) in humans were downloaded from 
Interologous Interaction Database (I2D) [28], comprising validated and predicted PPIs 
compiled from over 35 databases and literature. Gene ontology annotations (cellular 
components, biological processes and molecular functions) of protein targets were obtained 
from the enrichR [29] web server which provides up-to-date gene ontology annotations for 
gene-set enrichment analyses. Drug indications, i.e., drug to disease mapping and its clinical 
status, were downloaded from the Drug Repositioning Database (repoDB) [30]. Information on 
recorded adverse marketed drug reactions were obtained from SIDER, a database of drugs and 
side effects [31]. 
System design and implementation 
The whole pipeline—including data retrieval, filtration and quality control, similarity 
estimation, validation, and visualisation—was implemented in R providing a unified platform 
for ease of reuse and ongoing maintenance. Drug similarity matrix computation was 
implemented using parallel computing in R, enabling intensive and repetitive similarity 
computations to be efficiently run over multiple processors and cores on local and remote 
clusters. An interactive web interface was developed using R Shiny [32].  Three-dimensional 
visualisation of a queried drug’s molecular structure was implemented using the MolView [33] 
API. An interactive network view of an induced subnetwork comprising the queried drug and 
its interacting partners (i.e., significantly similar drugs) were visualised using the 
visNetwork R package which offers all the features available in vis.js library for Shiny R 
applications [34]. Records of drug-pair co-occurrence in PubMed abstracts were retrieved and 
processed using the easyPubMed R package. The pipeline implementation is available to the 
public, properly commented and well-documented for usage instructions. We recommend 
using a web browser that supports 3D graphics for MolView rendering. The web interface has 
been tested on Firefox, Google Chrome and Internet Explorer. 
Drug similarity estimation 
Chemical structure similarity 
Chemical structures of small molecule drugs were retrieved in SDF molecular format from 
DrugBank, release version 5.1.3 [35]. Invalid SDFs—i.e., those with NA values or with less 
than three columns in atom or bond blocks—were detected and removed. Atom pair descriptors 
were computed for valid compounds, and pairwise compound similarity, i.e., 𝛿𝑐(𝑑𝑖 , 𝑑𝑗), was 
estimated with atom pairs using the Tanimoto coefficient, which is defined as the proportion of 
atom pairs shared among two compounds divided by their union (Equation 1).  
𝛿𝑐(𝑑𝑖 , 𝑑𝑗) =  |𝐴𝑃𝑖 ∩ 𝐴𝑃𝑗| |𝐴𝑃𝑖 ∪ 𝐴𝑃𝑗|⁄ , (1) 
where 𝐴𝑃𝑖 and 𝐴𝑃𝑗 represent atom pairs of drugs 𝑑𝑖 and 𝑑𝑗 respectively; therefore, the 
numerator is the number of atom pairs which are common in both compounds, and 
denominator represents the number of all atom pairs of the two compounds.  These analyses 
were performed using the ChemmineR cheminformatics package in R [36]. 
Target protein sequence-based similarity  
Target sequences in FASTA format were retrieved for all small molecule drugs from 
DrugBank, release version 5.1.3 [37]. Pairwise protein sequence comparison was performed 
using the standard Needleman-Wunsch [38] dynamic programming algorithm for global 
alignment and the percentage of pairwise sequence identity [39] was reported as the 
corresponding sequence similarity. Drug-drug similarity based on sequence similarities of their 
targets was then estimated as per Equation 2:  
𝛿𝑡(𝑑𝑖, 𝑑𝑗) = (∑ max
∀𝑦∈𝑇𝑗
{𝑆(𝑥, 𝑦)}𝑥∈𝑇𝑖 + ∑ max∀𝑥∈𝑇𝑖
{𝑆(𝑦, 𝑥)}𝑦∈𝑇𝑗 ) (|𝑇𝑖| ∗ |𝑇𝑗|)⁄ , (2) 
where target-based similarity between drugs 𝑑𝑖 and 𝑑𝑗 is denoted by 𝛿𝑡(𝑑𝑖 , 𝑑𝑗). 𝑇𝑖 is a set of 
proteins targeted by drugs 𝑑𝑖. Likewise, 𝑇𝑗 is a set of proteins targeted by drugs 𝑑𝑗 and 𝑆(𝑥, 𝑦) 
is a symmetric sequence-based similarity measure between two protein targets, 𝑥 ∈ 𝑇𝑖 and 𝑦 ∈
𝑇𝑗. Overall, Equation 2 computes the best-match average in which each target of the first drug 
is paired only with the most similar term of the second one and vice versa. Sequence alignment 
and percentage of sequence identity were estimated using the Biostrings package of R 
[40]. 
Target Protein functional similarity  
In addition to sequence similarity, protein targets overrepresented by similar cellular functions 
would imply similarities in a drug’s mechanisms and downstream effects [41]. To that purpose, 
sets of Gene  Ontology (CO) terms of all three categories—i.e., cellular components (CC), 
molecular functions (MF) and biological processes (BP)—associated with each protein were 
retrieved from enrichR [29] libraries, version 2018. GO terms which were very specific (with ≤ 
15 associated genes) or very general (with ≥ 100 genes) were filtered out. The set of proteins 
associated with a drug was enriched including targets as well as their interacting proteins on 
the protein-protein interaction (PPI) network. The latter are functionally relevant proteins, the 
inclusion of which would enrich gene ontology annotations and improve subsequent statistical 
analyses. The Human PPI network was downloaded from I2D [28], version 2.9, and queried 
against the set of all protein targets; protein-to-gene mapping was performed using the 
AnnotationDbi package in R [42]. 
A GO term was then associated with a drug 𝑑𝑖 if overrepresented by its protein targets and 
their immediate interacting partners. In other words, a term would be enriched if there were a 
high enough number of 𝑑𝑖-related proteins annotated with the GO term implying that the 
functional association is statistically significant (p-value < 0.05 using Fisher’s exact test).    
Once each drug was annotated with enriched GO terms, the functional similarity between any 
two drugs, i.e., 𝛿𝑓(𝑑𝑖 , 𝑑𝑗), was determined by the semantic similarity of their associated GO 
terms as proposed by Wang et al. [43] using the topology of the GO graph structure. Pairwise 
semantic similarities between any two GO terms associated drug 𝑑𝑖 and 𝑑𝑗 were combined into 
a single semantic similarity measure using a best-match average strategy [43] and reported into 
a final similarity matrix. Semantic similarity estimation was performed using the mgoSim 
function from the GOSemSim R package [44].  
Drug-induced pathway similarity 
A drug-pair that induces identical or overlapping pathways implies similarities in mechanisms 
of drug actions providing relevant information for the study of drug similarities and 
repositioning [45]. Pathways induced by each small molecule drug were retrieved from KEGG, 
Release 91.0 [27]. The KEGGREST R package [46] (v 1.26.1) was used to invoke KEGG 
Restful APIs for collecting the list of KEGG pathways induced by each drug; ID mapping 
between DrugBank and KEGG Drug identifiers was performed using DrugBank external links, 
version 5.1.3.  
Pairwise similarity between any two pathways was estimated based on the similarity of their 
constituent genes using dice similarity. Then, for each drug pair 𝑑𝑖 and 𝑑𝑗, a pathway-based 
similarity score, i.e.,  𝛿𝑝(𝑑𝑖 , 𝑑𝑗), was estimated as per Equation 3: 
𝛿𝑝(𝑑𝑖, 𝑑𝑗) = max
∀𝑥∈𝑃𝑖,∀𝑦∈𝑃𝑗
{𝐷𝑆𝐶(𝑥, 𝑦)},  (3) 
where 𝑃𝑖 and 𝑃𝑗 are sets of pathways induced by drugs 𝑑𝑖 and 𝑑𝑗, respectively;  𝑥 and 𝑦 are two 
pathways represented as sets of their constituent genes, and 𝐷𝑆𝐶(𝑥, 𝑦) = 2|𝑥 ∩ 𝑦| (|𝑥| + |𝑦|)⁄  
is the dice similarity coefficient computing the relative overlap of the two pathways. The 
pathsim function from R BioCor package [47] was used to estimate 𝐷𝑆𝐶(. , . ) measures 
ranging from 0 to 1. Overall, Equation 3 indicates that the maximum pathway-based similarity 
would be attained if two drugs induce one or more identical pathway(s), and the minimum 
similarity of 0.0 is when there is no gene in common between any two pathways induced by 
the comparing drug pair.   
Results and discussion 
Database overview and statistics 
Figure 1 shows the overall scheme and construction of DrugSimDB and the web application.  
Table 1 summarises data sources used to generate the database and web interface along with 
statistics on retrieved data. Overall, 10,317 small-molecule drugs available in DrugBank, 
version 5.1.3 were considered and 6 distinct drug-drug similarity matrices were generated 
estimating measures based on similarities of chemical structures, target protein sequences, 
induced pathways and target protein function (cellular component, biological processes and 
molecular functions). The size of each similarity matrix is 10,317×10,317= 106,440,489 and 
values range from 0 to 1. Missing values indicate no relevant information is available about the 
comparing drugs and were retained for consistency in dimensions. The individual matrices 
were mean-aggregated to form a combined-score similarity matrix. To report relevant pairs, the 
combined matrix was filtered to exclude drugs with missing values across all individual 
matrices (496 out of 10,317) and those with no SMILE structure (639 out of 10,317). 
Additionally, drug pairs were excluded if neither of the two drugs were marketed/approved 
(resulting 23,865,948 drug pairs) with the assumption that repurposing would make sense only 
if the candidate had not failed to be approved for the disease of interest.  The final database 
was then organised as a data-table, where each row records a drug pair and columns correspond 
to individual similarity measures (×6),  the mean-aggregated score, its associated p-value 
(based on standardized z-score) and the corresponding false discovery rate (FDR) [48] adjusted 
p-value. The final data-table reports drug pairs with adjusted p-value < 0.05, yielding a total of 
238,635 unique pairs. 
       
Database access and usage notes 
A search interface for drug-similarity network 
We have developed a web application (http://vafaeelab.com/drugSimDB.html) using the Shiny 
R Studio project [32] to enable easy access to the DrugSimDB database and in-place 
investigation of drugs of interest (Figure 2A-G). With this application, users can query a drug 
(or list of drugs) and view similarity information on its interacting drugs retrieved from 
DrugSimDB (Figure 2B). The queried network—i.e., an induced sub-network comprising the 
queried drug and its interacting partners—would be displayed in an exportable tabular-view as 
well as an interactive network-view (Figure 2C). For a batch query, users can upload a text file 
containing drug names or DrugBank IDs and similarities among queried drugs would be shown 
in the tabular and network views. The tabular-view is sortable and includes information on 
interacting drug names, clinical statuses, individual and combined similarity measures with the 
queried drug(s), p-values, and adjusted p-values of the combined similarity scores. The induced 
sub-network of the queried drug(s) in the network-view is interactive and query-able; the edge 
width corresponds to the combined similarity score, and upon selecting an edge, a PubMed 
query is made with its incident drugs, and the search results are displayed as a table in a modal 
window (Figure 2D). Additionally, when a drug node is selected, it displays its side-effect 
information from the SIDER database. For any queried drug, in separate tabs, users can 
observe physiochemical properties of the queried drug (Figure 2E), its chemical structure in an 
interactive 3D view (Figure 2F), and its pharmacological properties (Figure 2G) providing an 
all-in-one view for further investigation of the drug of interest. For a multi-drug query, the 
structure view as well as physiochemical and pharmacological properties of each drug would 
be organised into a toggle list expandable upon clicking. Some example files are also provided 
to assist users on preparing input files for a batch query.  
Data download and statistics  
The interface enables users to bulk download the full DrugSimDB database as well as 
individual similarity matrices and other intermediately processed relevant files. Links to 
downloads are available in the Download page. Users can also view summary statistics of the 
database in the Statistics page and use the Help and Contact pages to get information on how to 
use the application and how to cite the database or contact producers for reporting any 
bugs/issues. 
Technical validation and relevance 
Drug-drug similarity network is scale-free 
Despite the phenomenal diversity of networks in nature, their architecture is usually governed 
by a few simple principles common to most real networks [49]. The most remarkable property 
of a network is characterised by the degree or connectivity of its nodes. Networks with power-
law degree distribution are called scale-free where most nodes have only a few links and a few 
nodes, often called hubs, have huge numbers of links holding the network together. 
Remarkably, biological networks among others, show a strong level of evidence for a scale-
free structure [50].     
We have shown that the DrugSimDB similarity network, where nodes are drugs and links 
represent pairwise similarity, illustrates scale-free topology (Figure 3A). The DrugSimDB 
network constitutes 4,141 unique drugs or nodes and 238,635 edges of similarity associations 
with p-value < 0.05. We performed a bootstrapping hypothesis test (using the poweRlaw 
package in R [51]) to statistically determine whether DrugSimDB’s network architecture 
follows a power-law distribution and received p-value=0.6 which does not reject the null 
hypothesis, indicating that the degree distribution is likely to be power-law.     
Aggregation of heterogeneous data improves the network coverage 
Integrating heterogeneous multisource biomedical data on drugs would adjust for missing 
information across individual data sources and increase the data coverage. This potentially 
alleviates the sparsity challenge and difficulty of handling drugs with no information [52].  
Figure 3B shows the proportion of drugs with no information across individual data sources 
and confirms that integration would reduce data sparsity. Drugs commonly have known valid 
chemical structures resulting a minimum rate of missing values (7.4% out of 10,317) for 
chemical similarity. Other information sources, however, show substantial proportions of 
missing values with drug-induced pathways being at the extreme range (90.3%). The latter can 
be further improved by incorporating other databases as well as predictions on drug-pathway 
associations [45, 53], gene-expression profiles [54, 55] and protein interactions [28].      
Drug-drug similarity network predicts repositioning candidates 
Drug similarity networks can be readily used for repositioning purposes upon the assumption 
that similar drugs are potentially repositionable for same indication(s). To validate this 
assumption, we used repoDB [30], as a standard database of drug repositioning successes and 
failures which contains 6,677 approved drug-indication pairs and 4,123 failed drug-indication 
pairs extracted from DrugCentral [56] and ClinicalTrials.gov [57].  DrugSimDB drug pairs 
(total of 238,635) were sorted ascendingly by their combined similarity scores; a pair is 
considered as a true positive (TP) when both drugs were approved for the same indication(s), 
and as a false positive (FP) if, for a same indication, one drug was approved and the other was 
not. We then plotted true positive rate, TPR (sensitivity) and false positive rate, FPR (1-
Specificity) at multiple cut-off values as implemented by the ROCit R package [58] and 
estimated the area under the ROC curve (AUC) as shown in Figure 3C. We received a 
competitive AUC value of 0.708 using the combined similarity as the predicted score which 
outperforms scoring based on individual similarity measures (Figure 3D). This corroborates 
previous observations that integrating heterogeneous data sources can improve repositioning 
performance [3, 59]    
Related works and comparison with Jaccard Index  
Drug-drug similarity networks have been frequently used in a variety of in-silico drug 
development applications. Supplementary Table 1 provides an illustrative list of recent 
studies where drug similarities were adopted as part of a larger computational pipeline to 
predict drug targets, identify drug-drug interactions, and reposition drugs for new indications, 
among others.  Regardless of the application, a mainstream approach to derive drug-drug 
similarities has been Jaccard similarity coefficient comparing properties (e.g., side-effects, 
targets, pathways) associated with any two drugs. While Jaccard-based similarity is a standard 
approach for comparing drugs across well-annotated properties (e.g., structural fingerprints), it 
has a limited capacity in deriving similarities for new or poorly annotated compounds. 
Additionally, when considering drug properties with a limited annotation coverage (e.g., 
induced pathways), drug pairs with overlapping properties are scarce, and thus the 
corresponding Jaccard based similarity matrix is extremely sparse upon studying a 
comprehensive set of compounds.  
DugSimDB improves upon baseline Jaccard similarity coefficient by comparing pathways at 
the gene level, by estimating targets’ sequence similarities and by integrating PPI information 
with gene-ontology semantic similarities. Figure 4 demonstrates that the adopted approaches 
enhance the coverage and connectivity of drug-drug similarity networks compared with 
Jaccard-driven alternatives. Figure 4A illustrates the distribution of similarity measures (after 
removing missing values) as the proportion of drug pairs whose similarities are less than the 
given cut-off. For instance, Jaccard Index on the pathway level shows 80% of zero similarity 
while this value reduces to 48% when comparing pathways at the gene level. Additionally, on 
the functional similarity, 99% of drug pairs have Jaccard similarity of less than 0.2 (i.e., 
similarity percentile), while in the DrugSimDB network, the percentile raises to 0.8 indicating 
that the adopted approach not only increased the coverage but also improved the strength of the 
similarity evidence. Figure 4B shows the mean degree of nodes. Figure 4C shows the number 
of drug pairs that are connected within the given distances where the shortest distance between 
any two nodes were estimated using breadth-first search algorithm as implemented by the 
igraph package in R [60]. In the Jaccard-based pathway similarity, for instance, nodes are 
merely reachable from their immediate partners forming several disconnected islands. 
Together, the plots clearly show the improved connectivity of the DrugSimDB networks which 
can enhance subsequent network diffusion approaches frequently used in different drug 
development applications (c.f.  Supplementary Table S1).   
Code and data availability 
To ensure the reproducibility of DrugSimDB, we have made the whole codebase (including 
any intermediate curation, processing and the web application) freely available for non-
commercial uses in GitHub (https://github.com/VafaeeLab/drugSimDB). The code and 
interface are well documented, and the database update is implemented as a semi-automated 
pipeline. This would enable any-time upgrade by users to accommodate for updates in source 
databases. The pipeline has been efficiently implemented for parallel processing and it is 
recommended to be run on high-performance computing (HPC) platforms to accelerate 
computations on large similarity matrices. 
Conclusions 
The DrugSimDB repository and its interface provide a comprehensive and easy-to-use resource 
to probe drug-drug similarities for a variety of drug development studies including, but not 
limited to, drug repositioning. The interface not only facilitates easy access to pairwise 
similarities via autocomplete browsing, exportable tables and interactive network 
visualisations, but also provides complementary information on the physiochemical properties, 
side-effects and pharmacology of queried drugs as well as PubMed evidence of any interacting, 
i.e., similar, drug pairs. Together, it provides an inclusive platform for similarity-based in-
silico drug studies, all in one view. We have developed a semi-automated, well-commented 
upgrade-pipeline to enable easy and periodic database upgrade not only for developers but also 
for users who are willing to access to the latest version of data sources at any time.   
Multiple lines of evidence regarding drug-related information have been derived from 
heterogeneous data sources to improve the coverage and prediction performance. Yet, 
DrugSimDB’s score-based prioritisation platform has the capacity to incorporate a multitude of 
other drug-related information—e.g., drug adverse effects, pharmacodynamics, drug-target 
secondary structures and drug-induced molecular omics, which are all within our future 
perspective to further enhance the current resource. In contrast to supervised computational 
methods, the score-based, unsupervised prediction as adopted by DrugSimDB, is not biased to 
training composition, is not affected by an unbalanced training set and can simply incorporate 
any rare and sparse feature with substantial missing values. DrugSimDB is basically a 
weighted, multi-modal scale-free network of drug-drug associations which offers the scope for 
various network-based analyses [52] such as community detection, network-based inference 
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Figure 1. Database content and construction. For 10,317 small-molecule drugs, DrugSimDB 
collects information on 1) drug chemical structures to estimate drug pairwise chemical 
similarity, 2) drug protein targets and protein sequences to estimate sequence-based target 
similarity, 3) drug-induced pathways and their constituent genes to estimate pathway-based 
similarities, and 4) GO annotations of protein targets and protein-protein interactions to 
identify functional similarities. The similarity scores are then mean-aggregated and filtered into 
a single matrix of combined similarities, i.e., DrugSimDB, which is made accessible and 
analysable via a user-friendly and interactive graphical user interface and complemented with 
other information for in-place drug investigation. Abbreviations: GO: Gene Ontology, CC: 
Cellular Component, MF: Molecular Function, BP: Biological Process. 
Figure2. Database interface and access. (A) The navigation bar, (B) Users query any drug 
name for information on its similarity information with other approved drugs and can choose to 
view the type of combined statistics (i.e., mean-aggregated score, p-value or adjusted p-value). 
A batch query is also supported, where users can upload a list of drug names or DrugBank IDs 
to view similarities among them. (C) An interactive tabular view of a DrugSimDB induced 
sub-network comprising the query drug and its interacting pairs; users can filter, sort, export 
and print the table. An interactive network view of the induced sub-network of the queried drug 
would also be rendered. (D) A tabular view of PubMed-curated literature list involving a drug-
pair when the user selects their corresponding edge in the network view. Panels 
describing/rendering the (E) Physiochemical, (F) interactive 3D structure, and the (G) 
Pharmacological properties of the queried drug are shown. Users can also view a colour-coded 
periodic table of chemical elements to aid in the understanding of its chemical structure in the 
Structure tab. 
Figure3. Technical validation and relevance. (A) This drug-drug similarity network 
illustrates a scale-free topology as observed in most of biological networks. (B) Integration of 
heterogenous data sources enhances information coverage reducing the number of missing 
values (i.e., drugs with no information) when compared to individual data sources. (C, D) 
Validated against RepoDB [30], a database of drug repositioning successes and failures, the 
combined similarity score of DrugSimDB drug-pairs yields a competitive AUC value of 0.708 
which outperforms the predicting power obtained from individual data sources. It retains a 
similar score compared to target-based similarity yet with substantially improved coverage. 
Figure 4. Comparison with Jaccard Index based on network-based properties. (A) The 
proportion of drug pairs whose similarity measure is equal or less than the given thresholds. 
(B) The mean degree of nodes in the DrugSimDB networks and the corresponding Jaccard-
based network; The error bar shows the standard error. (C) The number of drug pairs that are 
connected within the given distances (i.e., the number of links/edges between the two drugs is 
equal or less than the given threshold). Only the top 5% of similarity measures in target 
sequence-based and functional similarity matrices were retained in the DrugSimDB network 
and used for the calculation of degrees and distances. For each comparison, the pale colour 
corresponds to the Jaccard-based approach.  For functional similarity, only the GO category of 
biological processes (BP) was included in this visualisation; similar results obtained using 
other categories (i.e., MF and CC) as visualised in Supplementary Figure S1. 
Key points 
 DrugSimDB provides a comprehensive, integrative and extendable resource of drug-
drug similarities complemented with an interactive user-friendly web interface  
 DrugSimDB networks and individual similarity matrices cover an exhaustive list of 
currently approved and investigational drugs. The platform is easily updatable (by users 
and developers) to account for new drugs and information 
 DrugSimDB currently integrates information on drug chemical structures, protein 
targets and their primary structure, drug-induced pathways, gene ontology annotations 
of protein targets and protein-protein interactions.  
 The web interface facilitates access to further information on drugs’ pharmacology, 
physiochemical properties and side-effects as well as peer-reviewed evidence from the 
PubMed literature search engine on drug-pair co-occurrence.     
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